Thank you for joining us for this CME/CE Webcast,
Brainstorming with the Experts: Practical Approaches to the Complex World of HCV
.
This CME/CE program will include a brief pretest. Please start now by answering these 5 questions:
1.
The burden of hepatitis C-related disease is increasing,
Despite the decreasing incidence of HCV.
With the rate of increase proportional to the rate of increasing HCV incidence.
Although the death rate due to hepatocellular cancer is decreasing.
Although the burden could be expected to peak in the next decade owing to the age of the infected population and the extent to which infected individuals have already been diagnosed and treated.
2.
Insulin resistance is associated with nonresponse in HCV-infected patients treated with peginterferon/ribavirin.
True
False
3.
Which of the following statements most accurately reflects findings from maintenance therapy trials (ie, HALT-C and COPILOT) reported thus far?
Long-term peginterferon showed no histologic benefit compared with observation for most patients.
Long-term colchicine showed no histologic benefit compared with observation, except in patients with portal hypertension.
Long-term peginterferon showed no histologic benefit compared with observation, except in patients with portal hypertension.
Long-term peginterferon/ribavirin showed no histologic benefit compared with observation for most patients.
4.
How often do you currently
Always
Very Often
Sometimes
Not Very Often
Never
N/A
Monitor and facilitate adherence in your HCV-infected patients who are receiving peginterferon/ribavirin therapy with the goal of achieving at least 80% adherence to the prescribed treatment regimen?
Differentiate between nonresponse and relapse when deciding whether to re-treat a patient who failed prior peginterferon/ribavirin therapy?
5.
What is your current level of confidence in
Very Confident
Somewhat Confident
Not At All Confident
Discussing the potential role of STAT-C agents in the treatment of patients infected with hepatitis C?